Activation of protease calpain by oxidized and glycated LDL increases the degradation of endothelial nitric oxide synthase

J Cell Mol Med. 2009 Sep;13(9A):2899-910. doi: 10.1111/j.1582-4934.2008.00416.x. Epub 2008 Jun 28.

Abstract

Oxidation and glycation of low-density lipoprotein (LDL) promote vascular injury in diabetes; however, the mechanisms underlying this effect remain poorly defined. The present study was conducted to determine the effects of 'heavily oxidized' glycated LDL (HOG-LDL) on endothelial nitric oxide synthase (eNOS) function. Exposure of bovine aortic endothelial cells with HOG-LDL reduced eNOS protein levels in a concentration- and time-dependent manner, without altering eNOS mRNA levels. Reduced eNOS protein levels were accompanied by an increase in intracellular Ca(2+), augmented production of reactive oxygen species (ROS) and induction of Ca(2+)-dependent calpain activity. Neither eNOS reduction nor any of these other effects were observed in cells exposed to native LDL. Reduction of intracellular Ca(2+) levels abolished eNOS reduction by HOG-LDL, as did pharmacological or genetic through calcium channel blockers or calcium chelator BAPTA or inhibition of NAD(P)H oxidase (with apocynin) or inhibition of calpain (calpain 1-specific siRNA). Consistent with these results, HOG-LDL impaired acetylcholine-induced endothelium-dependent vasorelaxation of isolated mouse aortas, and pharmacological inhibition of calpain prevented this effect. HOG-LDL may impair endothelial function by inducing calpain-mediated eNOS degradation in a ROS- and Ca(2+)-dependent manner.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Calcium / metabolism
  • Calpain / antagonists & inhibitors
  • Calpain / metabolism*
  • Cattle
  • Cytoplasm / drug effects
  • Cytoplasm / enzymology
  • Enzyme Activation / drug effects
  • Glycation End Products, Advanced
  • Humans
  • Intracellular Space / drug effects
  • Intracellular Space / metabolism
  • Lipoproteins, LDL / pharmacology*
  • Mice
  • Mice, Inbred C57BL
  • NADPH Oxidases / metabolism
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type III / genetics
  • Nitric Oxide Synthase Type III / metabolism*
  • Protease Inhibitors / pharmacology
  • Proteasome Endopeptidase Complex / metabolism
  • Protein Processing, Post-Translational / drug effects*
  • Protein Transport / drug effects
  • Reactive Oxygen Species / metabolism
  • Time Factors
  • Transcription, Genetic / drug effects

Substances

  • Glycation End Products, Advanced
  • Lipoproteins, LDL
  • Protease Inhibitors
  • Reactive Oxygen Species
  • glycated lipoproteins, LDL
  • oxidized low density lipoprotein
  • Nitric Oxide
  • Nitric Oxide Synthase Type III
  • NADPH Oxidases
  • neutrophil cytosolic factor 1
  • Calpain
  • Proteasome Endopeptidase Complex
  • Calcium